Loading clinical trials...
Loading clinical trials...
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With RCHOP Chemotherapy and Rituximab (MabThera®) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma
Conditions
Interventions
rituximab
sargramostim
+9 more
Start Date
March 1, 2009
Primary Completion Date
March 1, 2011
Last Updated
August 2, 2013
NCT06263491
NCT07388563
NCT05139017
NCT06337318
NCT05529069
NCT07350863
Lead Sponsor
French Innovative Leukemia Organisation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions